Future Science Group
Browse
Supplementary table 1.docx (14.63 kB)

Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial - supplementary table

Download (14.63 kB)
dataset
posted on 2023-05-05, 13:46 authored by Mohammadreza Salehi, Farah Rezazade-Moayed, Hossein Khalili, Homa Hemati, Nasser Aghdami, Mohadese Dashtkoohi, Mohammad Dashtkoohi, Mohammad-Taghi Beig-Mohammadi, Masoud Ramezani, Mahboobeh Hajiabdolbaghi, Samrand Fattah-Ghazi

Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis.

Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h)

or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients

with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group.

No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also

comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical

treatment of nosocomial sepsis without serious concern regarding its safety.

History

Usage metrics

    Future Science Group

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC